Home > BIGG > Search result

    Results: 2

    Maribavir for treating refractory cytomegalovirus infection after transplant

    England. National Institute for Health and Care Excellence.
    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant. Commercial arrangement There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...
    Cytomegalovirus Infections/drug therapy, Antiviral Agents/therapeutic use, Hematopoietic Stem Cell Transplantation, Organ Transplantation
    Fulltext

    American Society of Transplantation and Cellular Therapy series 4: Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation

    Yong, Michelle; Lynn Shigle, Terri; Kim, Yae-Jean; Carpenter, Paul; Chemaly, Roy; Papanicolaou, Genevefa.
    Transplantation and Cellular Therapy; (), 2021
    The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new...
    Cytomegalovirus Infections/drug therapy, Cytomegalovirus/drug effects, Drug Resistance, Viral/drug effects, Hematopoietic Stem Cell Transplantation, Antiviral Agents/therapeutic use, Cytomegalovirus Infections/diagnosis
    Fulltext